EN DE
Watch Cohort for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cohort (CHRT) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Cohort stock £4.29, price £12.44, that is 65.5% below the price, quality 39 out of 100. Rating: strongly overvalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Industrials GB · ISIN GB00B0YD2B94

C Cohort logo Broad data Nov 6, 2026

Cohort

CHRT · LSE
Very expensive, weak quality

Our calculation puts a fair price 66% below what the stock costs today.

Low debt
Ranks above peers (9/13)
Broad data
Last quarter vs. a year ago: revenue +17%, profit +44%.
Expensive Growth (revenue 5y +16.4 %/yr in GBP)
Thin margins · 7.8% net margin (TTM)
1.4% dividend yield · Watch coverage
Moderate moat 52/100 · thin data
Fair value £4.29 · Strongly overvalued (−65.5%)
Quality 39/100
Negative free cash flow
Watch Cohort for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

£17.22 £3.66 Fair Value £4.29 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range £3.66 – £17.22 · fair‑value band £3.68 – £5.82 · the £12.44 price screens above the £4.29 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Cohort in your weekly email

Every Wednesday you see whether Cohort is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cohort plc provides various products and services in defense, security, and related markets in the United Kingdom, Germany, Portugal, Australia, North and South America, Asia Pacific, Africa, and other European countries.

Show moreShow less

It operates through Communications and Intelligence; and Sensors and Effectors segments. The company offers chess dynamic, a surveillance and fire control which provides bespoke solutions for land and maritime domains; and combat systems.

It also provides integrated command, control, and communications systems for warships and submarines; tactical radio, vehicle intercoms, field communications, and networking software and equipment; sonar systems and underwater communications; and electronic and surveillance technology services.

In addition, the company offers training and simulation; digital forensics; research, advice, and support services; sonar, radar, and visual for land and sea domains; and intelligent transport systems.

It offers its products and services for customers in the cyber and information, land, maritime, joint and strategic, air and space, and other markets. Cohort plc was incorporated in 2006 and is headquartered in Reading, the United Kingdom.

Stock analysis

Cohort (CHRT) currently trades at £12.44, while our model-based Fair Value estimate is £4.29, 66% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of £10.24 per share, and 2 of the 17 models we run sit above the £12.44 price.

Bear case: the Asset-Based group reads lowest at £0.8400, and 15 of the 17 models stay below the price. Data coverage for this calculation is high.

Scenario range: £3.68 (bear) to £5.82 (bull), the price of £12.44 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Industrials sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Cohort reported revenue of £306M in FY2026 versus £138M in FY2022, a compound +22.1%/yr. Reported net income was £23.9M in FY2026, compounding +27.0%/yr from FY2022.

Key figures

Market cap £580M Small · P/E ratio 24.4 · P/S ratio 1.89 · EPS (TTM) £0.5100 · Dividend yield 1.4% · Net margin 7.8% · Return on equity 13.9% · Return on assets (EBIT) 7.0% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).

What moves the price

The share trades about 16% below its 52-week high and 39% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Industrials peers we cover trades at −23% fair-value upside, at −66%, CHRT screens richer than that median.

Fair Value models

Bear £3.68 Fair Value £4.29 Bull £5.82
Price £12.44 · Downside -65.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (£0.1741 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income £3.68 £4.29 £5.82 76
Owner Earnings £0.8400 £1.43 £2.39 74
EPV £4.98 £5.70 £6.30 74
All 17 models by family
DCF Models
Owner Earnings £0.8400 £1.43 £2.39 74
Earnings-Based
Graham-Dodd £3.53 £17.26 £23.79 64
Lynch FV £4.64 £6.62 £8.61 61
PEG = 1.0 £4.64 £6.62 £8.61 57
EPV £4.98 £5.70 £6.30 74
Dividend Discount
Gordon GGM £1.37 £2.58 £3.68 67
DDM Multi-Stage £1.37 £2.30 £2.74 67
Multiples
P/E Multiple £8.17 £10.89 £13.61 63
P/S Multiple £6.61 £8.82 £11.02 58
P/B Multiple £4.22 £5.63 £7.03 55
EV/EBIT £8.57 £11.48 £14.38 66
EV/EBITDA £9.35 £12.51 £15.68 67
EV/Revenue £6.08 £8.74 £11.41 53
Asset-Based
NCAV (Graham) £0.6300 £0.8400 £1.25 54
Economic Profit
Residual Income £3.68 £4.29 £5.82 76
ROIC Compounder £5.36 £7.02 £9.23 72
Growth Earnings
Growth-Adj P/E £7.17 £10.24 £13.31 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 45
How much profit the company makes from its sales and capital
Quality Growth 52
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 78
Debt, balance sheet and risk of trouble
Investment 26
Does it invest with discipline instead of growing at any price?
Low Volatility 65
How calm the share price moves, does not count
Price momentum 39
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 47
Distance to the 52-week high, does not count
New shares 22
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+13.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.4%
Start year 2021 (pandemic). Over 10 years: +10.5% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.4%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
+22.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+21.0%
Dividend (yield on the price)1.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.18.0% vs 14.1%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 10%
Pace: the 5-year rate starts in 2021 (pandemic)

CHRT screens overvalued: fair value 66% below the price. Compare with General Electric Company →

Compare Cohort with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Aerospace & Defense · 238 stocks

Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 39 · Bottom 25%
Fair Value upside −65.5% · Below median
Profitability
Return on equity (12 months) 13.9% · Above median
Return on assets 5.7% · Above median
Net margin (12 months) 7.8% · Above median
Operating margin (12 months) 15.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 17.0% · Above median
Dividend yield (12 months) 1.4% · Above median
Balance sheet
Debt / equity 0.25× · Above median

Valuation Multiplesvs Aerospace & Defense median · lower = cheaper

P/E (12 months) 24.4× · Cheaper than median
P/B 3.11× · Pricier than median
P/S (12 months) 1.89× · Cheaper than median
EV/EBITDA 13.0× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)85 · sector 65
PAST (return on equity)56 · sector 41
HEALTH (low debt)87 · sector 94
DIVIDEND (yield)29 · sector 19

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Weapons Defense

Similar stocks

10 more Aerospace & Defense stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Safran SA SAF €295.50 €327.36 +11% vs CHRT
Honeywell Aerospace Inc HONA $152.92 $168.21 +10% vs CHRT
TransDigm Group TDG $1,197 $1,308 +9% vs CHRT
Lockheed Martin Corporation LMT $567.08 $439.21 −23% vs CHRT
General Dynamics Corporation GD $354.06 $274.19 −23% vs CHRT
Northrop Grumman Corporation NOC $525.01 $382.98 −27% vs CHRT
Airbus SE AIR €196.40 €112.14 −43% vs CHRT
RTX Corporation RTX $189.53 $88.19 −53% vs CHRT
General Electric Company GE $323.24 $92.26 −71% vs CHRT
Howmet Aerospace Inc HWM $205.81 $52.65 −74% vs CHRT

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cohort: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Cohort Fair Value". https://www.fairvalue-calculator.com/stock/CHRT

Frequently asked questions

Is Cohort (CHRT) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of £4.29 versus a price of £12.44, about 66% lower (overvalued).
What is the fair value of CHRT?
Our model-based fair value for Cohort is £4.29 (as of Nov 6, 2026), built from audited fundamentals. The current price: £12.44.
What is the quality score of CHRT?
Cohort has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cohort (CHRT)?
Our model-based price target is the fair value of £4.29 (as of Nov 6, 2026) from 17 valuation models. Cautious scenario £3.68, optimistic scenario £5.82. It is a calculation from audited fundamentals, not an analyst target.
What is the Cohort stock forecast for 2026?
Our models put fair value at £4.29, about 66% lower versus a price of £12.44 (overvalued). Cautious scenario £3.68, optimistic scenario £5.82. The calculation is refreshed regularly with new filings.
What is the revenue of Cohort (CHRT)?
Cohort reported trailing-twelve-month revenue of about £306M (latest available figure, as of Nov 6, 2026).
Does Cohort pay a dividend?
Cohort currently shows a dividend yield of 1.44% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Cohort (CHRT) and when is the ex-dividend date?
Cohort pays a dividend of £0.179 per share a year, a dividend yield of 1.4%. The last ex-dividend date was Aug 20, 2026. A dividend has been paid every year since at least 2006. The payout ratio is 35.1% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Cohort (CHRT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cohort it is £4.29 per share (as of Nov 6, 2026), against a price of £12.44. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Cohort stock overvalued or undervalued in 2026?
As of Nov 6, 2026, CHRT trades above its calculated fair value: price £12.44, fair value £4.29, a gap of about −66% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CHRT?
No. The price is what the market pays today (£12.44); the fair value is what the company's own numbers justify (£4.29). For Cohort the two are £8.15 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cohort worth?
The market values Cohort at about £580M (market capitalisation, as of Nov 6, 2026). Per share that is £12.44; our models calculate a fair value of £4.29 per share.
What do the bullish and bearish scenarios say about CHRT?
Our models span a range for Cohort: cautious scenario £3.68, base £4.29, optimistic £5.82 per share (as of Nov 6, 2026, price £12.44). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CHRT?
Cohort trades at a price-to-earnings ratio of 24.4 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of £4.29 is built from several models across several years. Other multiples: P/B 3.1, P/S 1.9, EV/EBITDA 13.0.
How solid is the balance sheet of Cohort (CHRT)?
Balance-sheet figures for Cohort (as of Nov 6, 2026): return on equity 13.9%, debt of 0.25 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is CHRT from its 52-week high?
Cohort trades at £12.44, about 16% below its 52-week high of £14.74 and 39% above the low of £8.92 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of £4.29 is for.
Which stocks are comparable to Cohort?
From the same area (Industrials) we also value General Electric Company, RTX Corporation, Airbus SE, Safran SA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cohort stock attractive at the current price?
The data as of Nov 6, 2026: price £12.44, calculated fair value £4.29 (−66%), Quality Score 39/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CHRT calculated?
We run Cohort through 17 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of £4.29 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Cohort itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cohort (CHRT)?
The closing price on Nov 6, 2026 was £12.44. Our model-based fair value is £4.29, about 66% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cohort right now?
The price sits above even our optimistic bull case (£5.82). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts.
Where does the earnings growth of Cohort (CHRT) come from?
Earnings per share at Cohort grew +13.9 % a year from 2015 to 2026. Broken into its drivers: revenue per share +9.5 %, EBIT margin +11.8 %, tax rate −2.4 %, residual (interest, one-offs) −4.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Cohort

How large is the market capitalisation of Cohort (CHRT)?
The market capitalisation of Cohort is £580M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cohort (CHRT)?
The price-to-sales ratio of Cohort is 1.89 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cohort (CHRT)?
Earnings per share at Cohort are £0.5100 (price ÷ EPS = P/E 24.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Cohort (CHRT)?
The dividend yield of Cohort is 1.4% (payout 35.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Cohort (CHRT)?
The net margin of Cohort is 7.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cohort (CHRT)?
The return on equity (ROE) of Cohort is 13.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cohort (CHRT)?
On an EBIT basis the return on assets of Cohort is 7.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cohort (CHRT)?
The operating margin of Cohort is 15.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cohort (CHRT)?
Revenue at Cohort is growing +17.0% versus a year earlier (3y avg +18.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cohort (CHRT)?
Earnings per share at Cohort are growing +44.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Cohort (CHRT) generate?
The free cash flow of Cohort is −£5.9M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cohort (CHRT) carry?
The net debt of Cohort is £6.7M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Cohort in the live analysis

One click puts Cohort on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.